Clinical trials

  • cagrilintide (NNC0174-0833) | semaglutide (NNC0113-0217) for Overweight | Obesity
  • ZILTIVEKIMAB for Atherosclerotic cardiovascular disease | Chronic kidney disease | Systemic inflammation
  • CONCIZUMAB for Haemophilia A|Haemophilia B
  • CAGRILINTIDE, SEMAGLUTIDE for Cardiovascular disease|Type 2 diabetes mellitus
  • GIREDESTRANT for Estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer
  • GSK3862995B for Chronic obstructive pulmonary disease
  • BELANTAMAB MAFODOTIN for Relapsed/Refractory Multiple Myeloma
  • CCTX-001 for Acute myeloid leukemia (relapsed/refractory)
  • PEMBROLIZUMAB for Renal cell carcinoma
  • CONCIZUMAB for Haemophilia A | Haemophilia B
  • TRIPTORELIN for Menopause
  • CAL101 for Idiopathic pulmonary fibrosis